PNC Financial Services Group Inc. Acquires 4,834 Shares of Gilead Sciences, Inc. $GILD

PNC Financial Services Group Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 420,970 shares of the biopharmaceutical company’s stock after acquiring an additional 4,834 shares during the period. PNC Financial Services Group Inc.’s holdings in Gilead Sciences were worth $46,728,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Csenge Advisory Group lifted its position in shares of Gilead Sciences by 319.0% in the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 16,288 shares during the period. Cookson Peirce & Co. Inc. increased its position in shares of Gilead Sciences by 249.1% during the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after buying an additional 7,168 shares during the period. Railway Pension Investments Ltd raised its stake in Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after buying an additional 42,200 shares in the last quarter. TriaGen Wealth Management LLC bought a new position in Gilead Sciences in the third quarter worth about $1,274,000. Finally, iA Global Asset Management Inc. lifted its holdings in Gilead Sciences by 11.6% in the third quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after buying an additional 23,046 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 2.1%

Shares of NASDAQ:GILD opened at $154.98 on Tuesday. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock has a fifty day simple moving average of $130.94 and a two-hundred day simple moving average of $122.68. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The stock has a market capitalization of $192.28 billion, a price-to-earnings ratio of 22.89, a PEG ratio of 2.06 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is currently 46.68%.

Analysts Set New Price Targets

A number of research firms have weighed in on GILD. Daiwa Securities Group upped their target price on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Deutsche Bank Aktiengesellschaft lifted their price target on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Wolfe Research upped their price target on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Argus raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, January 8th. Twenty-three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $152.50.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the transaction, the chief executive officer directly owned 613,912 shares of the company’s stock, valued at $92,086,800. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the insider directly owned 103,221 shares in the company, valued at $12,831,402.51. This trade represents a 2.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 288,891 shares of company stock worth $40,303,946. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.